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Case Report
Yellow nail syndrome after allogeneic 
haematopoietic stem cell transplantation in 
two patients with multiple myeloma
Céline Gregoire1, Julien Guiot2, Gaëlle Vertenoeil1, Évelyne Willems1, Kaoutar 
Hafraoui1, Jean-Louis Corhay2, Renaud Louis2, Yves Beguin1
1Department of Medicine, Division of Hematology, CHU of Liège and University of Liège, Liège, Belgium, 
2Department of Medicine, Division of Pneumology, CHU of Liège and University of Liège, Liège, Belgium
Objective and Importance: Yellow nail syndrome (YNS) is a rare disorder of unknown aetiology characterized 
by the triad of yellow nails, lymphoedema and respiratory manifestations. About 200 cases have been reported, 
but a lot of patients probably elude proper diagnosis because of both variability of symptoms and ignorance of 
this syndrome by many physicians. The pathogenesis remains unclear, and could involve functional lymphatic 
abnormalities, microvasculopathy or lymphocyte deficiency, but none of these hypotheses seems fully satisfactory.
Clinical Presentation: We report for the first time two cases of YNS associated with multiple myeloma relapsing 
after non-myeloablative haematopoietic cell transplantation (HCT). In these two cases, onset or worsening of 
YNS symptoms followed graft-versus-host disease (GvHD) manifestations.
Intervention: Corticosteroids given to treat GvHD also improved YNS manifestations.
Conclusion: YNS after HCT might be a microvascular manifestation of endothelial GvHD and corticosteroids 
might be an effective treatment.
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Introduction
Yellow nail syndrome (YNS) is a rare disorder of unknown 
aetiology characterized by the triad of yellow nails, lym-
phoedema and respiratory manifestations. It was first 
described by Samman and White in 1964 and about 200 
cases have been reported. We report for the first time two 
cases of YNS associated with graft-versus-host-disease 
(GvHD) after non-myeloablative (NMA) haematopoietic 
cell transplantation (HCT) for multiple myeloma (MM).
Case 1
The first patient was diagnosed with light chain MM at 
the age of 41 and treated by chemotherapy, three autol-
ogous HCT and an allogeneic NMA-HCT, achieving a 
very good partial response (VGPR). Immunosuppressive 
regimen was based on the association of mycophenolate 
mofetil (MMF) and tacrolimus, discontinued at day 42 
and day 240 post-transplantation, respectively. Fifteen 
months after transplantation, the patient developed chronic 
cutaneous GvHD, respecting the nails, concurrently with 
bilateral lower limb oedema, sinusitis and pleuro–pericar-
dial effusion. The pleural fluid was a monocytic exudate 
(white blood cells 690/μL with 21% lymphocytes and 
78% monocytes, proteins 39 g/L, lactate dehydrogenase 
202 UI/L), without any micro-organism or malignant cell. 
These manifestations were identified as GvHD-associated 
serositis and partially improved with corticosteroids, ciclo-
sporine and furosemide. Except for limited probable lung 
aspergillosis (treated initially with voriconazole, then 
with amphotericin B), the patient remained stable for six 
months, until a surgical procedure was complicated by 
respiratory distress. Thoracic scanner showed pleuro–per-
icardial effusion, ground grass infiltrates and nodular 
lesions. Antibiotic, antifungal and diuretic therapy led to 
a favourable evolution. Three months later, MM relapsed 
and was treated successively with thalidomide and borte-
zomib (allowing a VGPR), while immunosuppressive 
drugs were stopped. Several months later, the patient 
developed a bronchopneumonia with pleuro–pericardial 
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effusion, concurrently with a new myeloma progression. 
After failure of bortezomib and dexamethasone, the former 
was replaced by lenalidomide, and complete remission 
(CR) as well as significant improvement of the cardiopul-
monary manifestations were observed. Chronic symptoms 
of sinusitis, respiratory infections and pleuro–pericardial 
effusion fluctuated during two years, but significantly 
worsened, together with apparition of onycholysis, when 
ocular GvHD started. After an initial improvement of 
anasarca with furosemide, the patient developed a septic 
shock of pulmonary origin, with pleuritis and pericar-
dial lymphocytic effusion, requiring a pleura–pericardial 
window. YNS was then diagnosed, as yellow nails were 
observed, together with bronchopneumonia, lower limb 
lymphedema and bilateral pleural effusion. After a good 
response to empirical antibiotherapy, long-term treatment 
consisted in pulmonary rehabilitation, low-dose long-term 
corticosteroid therapy and topical vitamin E applied to the 
nails. The evolution has been excellent, with less invalidat-
ing ocular symptoms, less frequent respiratory infections 
and sinusitis, and reduced dyspnoea and lymphoedema, 
but no objective improvement of pulmonary function 
(restrictive and small airways obstructive syndrome) and 
nail abnormalities, and persisting ground glass opacities 
on CT-scan.
Case 2
The second patient was diagnosed with immunoglobulin 
G kappa MM at the age of 62, and treated with chemo-
therapy and double autotransplantation, followed by a 
NMA-HCT from a HLA-identical sibling, leading to a 
CR. Immunosuppressive regimen was based on the asso-
ciation of MMF, discontinued at day 28 post-transplanta-
tion, and tacrolimus. While still receiving tacrolimus, the 
patient developed cutaneous and digestive acute GvHD, 
treated with corticosteroids. Two months later, while cor-
ticosteroids were being tapered, he developed an auto-
immune haemolytic anaemia secondary to Epstein–Barr 
virus reactivation (resistant to corticosteroids, intravenous 
immunoglobulins and rituximab, eventually cured after 
splenectomy). Around 15 months later, as all immuno-
suppressive treatments had long been stopped, he suf-
fered from tetraparesis and tabetic ataxia caused by a 
demyelinating inflammatory myelitis, whose aetiology 
was probably dysimmune (infectious and inflammatory 
causes having been excluded). This myelitis was suc-
cessfully treated with corticosteroids, which were tapered 
over 2 months. In this context of immunosuppression and 
hypogammaglobulinemia, the patient had recurrent res-
piratory tract infections and sinusitis. One month after 
discontinuation of corticosteroids, ungueal dystrophy 
was noted for the first time (Fig. 1), without any other 
sign of GvHD. Approximately one year later, myeloma 
relapsed, and donor lymphocytes infusion (DLI) allowed 
a new CR. Eighteen months after DLI, the patient suffered 
from ocular GvHD, treated with topical corticosteroids. 
One month later, he developed abundant right pleural effu-
sion and non-pitting lower limb edema, associated with 
diffuse broncho-bronchiolopathic syndrome, mediastinal 
lymphadenopathies and a moderate restrictive syndrome 
with diminished diffusing capacity for carbon monoxide. 
Renal and cardiac functions were normal. The pleural 
fluid was a haemorrhagic lymphocytic exudate (red blood 
cells 11,600/μL, white blood cells 6264/μL with 74% 
lymphocytes and 24% monocytes, lactate dehydrogenase 
100 UI/L, proteins 52 g/L), without micro-organism or 
malignant cell. Diuretics allowed an initial resolution of 
symptoms, but they reappeared, associated with yellow 
dystrophic nails, leading to the diagnosis of YNS. The 
diuretic treatment was intensified, but symptoms recurred 
after two bronchopneumonias with pleural effusion requir-
ing iterative drainage and eventually a pleuroscopy with 
talc pleurodesis. Biopsies of the pleura showed chronic 
lymphocytic pleuritis. As ocular GvHD worsened, the 
patient received a three-week course of systemic corti-
costeroids, allowing a healing of the keratitis, as well as a 
partial regression of symptoms of YNS, with less yellow 
nails, diminished lymphoedema and less frequent sinusitis.
Figure 1 Yellow nails. Ungueal dystrophy (patient 2): nails are yellow, thickened, with excessive curvature and onycholysis.
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Discussion
YNS is characterized by the triad of yellow nails, lym-
phoedema and respiratory manifestations. As the manifes-
tations are inconstant, only two of the three features are 
required. A lot of patients probably elude proper diagnosis 
because of both variability of symptoms and ignorance 
of this syndrome by many physicians. Nails may be yel-
low with slow growth, thickening, excessive curvature or 
onycholysis. Non-pitting bilateral lymphedema of lower 
extremities is often present.1 Cardio-respiratory manifes-
tations include cough, dyspnoea, pericardial and bilateral 
pleural effusions, bronchiectasis, respiratory tract infec-
tions and chronic sinusitis. Pleural fluid is typically an 
exudate by the protein criterion but a transudate by the 
lactate dehydrogenase criterion, sometimes a chylotho-
rax. Cellular analysis shows lymphocytic predominance 
and no micro-organism. Pulmonary function is frequently 
abnormal, with a reversible obstructive pattern most com-
monly observed; restrictive lung defects are less common 
and usually associated with the presence of a pleural effu-
sion (as seen in our two patients).2 Treatment of YNS is 
essentially symptomatic. Topical steroids or vitamin E 
are sometimes applied to the nails. Improvements of nail 
abnormalities and lymphoedema have been noted with 
better control of respiratory manifestations.1 In patients 
with immune deficiency, immunoglobulin administration 
may be useful.3 In our patients, corticotherapy allowed 
an improvement of both GvHD and YNS manifestations.
YNS has been described in association with a vari-
ety of conditions1,3 such as malignancies, including lung 
cancer (4 cases), breast cancer (4 cases), or haematologic 
malignancies (1 case of macroglobulinemia, 2 cases of 
non-Hodgkin’s lymphoma and 1 case of mycosis fun-
goides), immunodeficiencies (12 cases), rheumatoid arthri-
tis (7 cases), thiol compounds such as bucillamine used 
in rheumatoid arthritis (41 cases), titanium released by 
implants (34 cases), tuberculosis (3 cases), nephrotic syn-
drome (2 cases), exudative enteropathy (2 cases), … YNS 
has never been described as an association with MM or 
GvHD. In our cases, some of the manifestations appeared 
a few months before diagnosis of disease relapse, and were 
improved after treatment of these relapses. Nevertheless, 
this association was inconstant as patients in CR of their 
MM were still suffering from YNS symptoms. It rather 
appears that onset or worsening of YNS symptoms fol-
lowed GvHD manifestations.
The pathogenesis of YNS remains unclear. A first series 
of hypotheses involved functional or anatomic lymphatic 
abnormalities. Nail manifestations might be due to ectasia 
of endothelium-lined lymphatic vessels or to lipofuscin, 1 
and recurrent airway infections might be due to impaired 
lymphatic drainage, resulting in delayed bacterial clear-
ance. Conversely, infections are considered by some as 
a trigger overwhelming a ‘saturated’ dysfunctional lym-
phatic network.1 Some authors have also suggested that 
YNS might be due to lymphocyte deficiency, second-
ary to their migration into pleural fluid and dermis.3 A 
more recent hypothesis involves microvasculopathy with 
increased capillary permeability and protein leakage, 
resulting in pleural effusion (with a high protein content), 
as well as hypogammaglobulinemia and lymphopenia con-
tributing to the high rate of respiratory infections.4 This 
theory is supported by the reports associating YNS and 
exsudative enteropathy or nephrotic syndrome. There is 
also increasing evidence of the involvement of endothelial 
damage by alloreactive T cells in GvHD, in addition to 
the classic epithelial damage.5–7 In our cases, YNS might 
therefore be a microvascular manifestation of GvHD.
Conclusion
YNS is a disorder characterized by yellow nails, lymphoe-
dema and respiratory manifestations. We report the first 
two cases of YNS associated with MM and NMA-HCT. 
In these cases, YNS might be a microvascular manifes-
tation of GvHD and corticosteroids might be an effective 
treatment.
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